Andrew N. Schiff, MD

Observer

Andrew Schiff, MD, joined Aisling Capital, a healthcare focused private equity fund based in New York in September of 1999 and has been involved in their investment activities since then. Prior to joining the fund, Dr. Schiff practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as a clinical assistant professor of medicine. He currently serves as a director of ARMGO Pharma, Inc., Powervision, Inc. and Zeltiq Aesthetics, Inc. Previously, he served as a director of Agile Therapeutics, Miramar Laboratories, Dynova Laboratories Transenterix, SkinMedica, Adams Respiratory Therapeutics, ArgiNOx Pharmaceuticals, Barrier Therapeutics, Bioenvision, Cempra Pharmaceuticals, CardioKine, Myogen and SirionTherapeutics. He is a long-time supporter of the Visiting Nurse Service of New York as well as other charitable organizations. Dr. Schiff received his medical doctorate from Cornell University Medical College, his master’s degree in business from Columbia University, and his bachelor’s degree with honors in neuroscience from Brown University.